Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2003

View Archived Issues

Gastrointestinal safety of AZD-3582 demonstrated in humans

Efficacy and tolerance of MS-275 in patients with refractory tumors

Etanercept monotherapy for plaque psoriasis

Ximelagatran demonstrates efficacy in VTE

Beneficial effects of UCB-34714 in neuropathy and epilepsy

Antitumor effects of TZT-1027 in advanced cancer patients

Vernalis updates development status of key R&D programs

R&D highlights from the 3rd Annual Biotech in Europe Investor Forum: Lorantis

Organon and CARIM join forces in atherosclerosis research

Wex updates Tectin progress

Novel MAO-B inhibitors and their use patented by Roche

New muscarinic antagonists identified at Schering

Aventis describes new series of Th2 cell modulators

New JNK3 inhibitors with potential utility in cerebral ischemia and other CNS disorders

Novel antibacterial agents covered by Bayer patent

Enanta team presents new semisynthetic macrolide antibiotics

NGF-modulating compound in development at Krenitsky for neurodegenerative conditions

Enrollment completed in phase IIa BPH study of BXL-628

BresaGen spin-off to create leading stem cell therapy company

Gadovist 1.0 receives E.U. approval for MRA

R&D highlights from the 3rd Annual Biotech in Europe Investor Forum: Opexa Pharmaceuticals

Solvay describes preclinical studies with centrally available NK1 receptor antagonist SLV-323

ER-022604: a neurotrophic factor-like compound with potential in motoneuronal diseases

Inhibition of GSK-3beta reduces neuronal death in culture and in animal model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...